Oramed rises as partner completes oral insulin trial, seeks China approval

Oramed Pharmaceuticals

15/05/2023 15:29

** Shares of Oramed Pharmaceuticals Inc  ORMP.O  34.3% at
$3.8
    ** Drug developer says its Chinese strategic partner Hefei
Tianhui Biotechnology Co Ltd (HTIT) completed late-stage trials
of oral insulin in type 2 diabetes (T2D) treatment in China
under a differentiated study protocol
    ** T2D a chronic condition that affects the way the body
processes blood sugar
    ** HTIT is now moving towards Chinese marketing approval and
has submitted the data to the regulatory authorities - ORMP
    ** Including session's gain, ORMP stock down ~68% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))